“…Another category of K V 1.3 inhibitors has been developed from peptide toxins, such as scorpion toxins (e.g., Charybdotoxin (ChTx), Margatoxin (MgTx), Agitoxin 2 (AgTx-2), α-KTx3.7 (OsK-1), and snake toxins (e.g., BF9) (Bartok et al, 2014;Chen et al, 2001;Mouhat et al, 2005;Pimentel et al, 2008). These peptidic K V and in vivo studies to demonstrate the potential therapeutic effects of blocking K V 1.3mediated K + currents in different disease models, including PD (Koo et al, 1997;Tubert et al, 2016;Yang et al, 2014a). One prominent example is ShK, a 35-residue disulfide-rich peptide toxin purified from the sea anemone, Stichodactyla helianthus (Norton et al, 2004;Tudor et al, 1996).…”